Although EGFR TKIs show good response rates and progression free survival in NSCLC patients with EGFR gene mutations, acquired resistance to TKIs therapy is commonly reported, often due to multiple mechanisms including EGFR additional mutations48,49, activation of redundant kinase signaling pathway, or EGFR downstream molecules2. Here, EGFR is linked to non-small cell lung carcinoma.